The risk of cardiovascular events with increased apolipoprotein CIII: A systematic review and meta-analysis (Q26801304)

Journal of Clinical Lipidology

PubMed

published in

1 reference

Meta-analysis of Observational Studies in Epidemiology: A Proposal for Reporting

PubMed

volume

9

0 references

page(s)

498-510

0 references

issue

4

0 references

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACL.2015.05.002

7 January 2021

Quantifying heterogeneity in a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACL.2015.05.002

7 January 2021

Influence of apolipoproteins on the anatomical distribution of arterial disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACL.2015.05.002

7 January 2021

Plasma apolipoprotein A-I, A-II, B, E and C-III containing particles in men with premature coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACL.2015.05.002

7 January 2021

Meta-analysis in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACL.2015.05.002

7 January 2021

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACL.2015.05.002

7 January 2021

Inhibition of lipoprotein lipase by an apoprotein of human very low density lipoprotein

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACL.2015.05.002

7 January 2021

Small genetic effects in complex diseases: a review of regulatory sequence variants in dyslipoproteinemia and atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACL.2015.05.002

7 January 2021

Apolipoprotein C-III, a strong discriminant of coronary risk in men and a determinant of the metabolic syndrome in both genders.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACL.2015.05.002

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACL.2015.05.002

7 January 2021

Plasma lipoproteins, apoproteins and cardiovascular disease in type 2 diabetic patients. A nine-year follow-up study

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACL.2015.05.002

7 January 2021

Apolipoprotein C-III: understanding an emerging cardiovascular risk factor

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACL.2015.05.002

7 January 2021

Loss-of-function mutations in APOC3, triglycerides, and coronary disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACL.2015.05.002

7 January 2021

Methods for Trend Estimation from Summarized Dose-Response Data, with Applications to Meta-Analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACL.2015.05.002

7 January 2021

Updates on apolipoprotein CIII: fulfilling promise as a therapeutic target for hypertriglyceridemia and cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACL.2015.05.002

7 January 2021

Apolipoprotein C-III predicts cardiovascular mortality in severe coronary artery disease and is associated with an enhanced plasma thrombin generation.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACL.2015.05.002

7 January 2021

An ABC of apolipoprotein C-III: a clinically useful new cardiovascular risk factor?

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACL.2015.05.002

7 January 2021

A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACL.2015.05.002

7 January 2021

LDL containing apolipoprotein CIII is an independent risk factor for coronary events in diabetic patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACL.2015.05.002

7 January 2021

Common genomic variation in the APOC3 promoter associated with variation in plasma lipoproteins

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACL.2015.05.002

7 January 2021

VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACL.2015.05.002

7 January 2021

Metabolism of very-low-density lipoprotein and low-density lipoprotein containing apolipoprotein C-III and not other small apolipoproteins

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACL.2015.05.002

7 January 2021

Apolipoprotein CIII in apolipoprotein B lipoproteins enhances the adhesion of human monocytic cells to endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACL.2015.05.002

7 January 2021

Apolipoprotein CIII induces expression of vascular cell adhesion molecule-1 in vascular endothelial cells and increases adhesion of monocytic cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACL.2015.05.002

7 January 2021

Apolipoprotein C-III and the metabolic basis for hypertriglyceridemia and the dense low-density lipoprotein phenotype

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACL.2015.05.002

7 January 2021

Low-density lipoproteins containing apolipoprotein C-III and the risk of coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACL.2015.05.002

7 January 2021

Apolipoprotein C-III as a Potential Modulator of the Association Between HDL-Cholesterol and Incident Coronary Heart Disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACL.2015.05.002

7 January 2021

Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACL.2015.05.002

7 January 2021

Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACL.2015.05.002

7 January 2021

Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACL.2015.05.002

7 January 2021

Chylomicronemia due to apolipoprotein CIII overexpression in apolipoprotein E-null mice. Apolipoprotein CIII-induced hypertriglyceridemia is not mediated by effects on apolipoprotein E

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACL.2015.05.002

7 January 2021

Association between the -455T>C promoter polymorphism of the APOC3 gene and the metabolic syndrome in a multi-ethnic sample

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACL.2015.05.002

7 January 2021

Apolipoprotein C-III, metabolic syndrome, and risk of coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACL.2015.05.002

7 January 2021

Rapid turnover of apolipoprotein C-III-containing triglyceride-rich lipoproteins contributing to the formation of LDL subfractions

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACL.2015.05.002

7 January 2021

Expression of apolipoprotein C-III in McA-RH7777 cells enhances VLDL assembly and secretion under lipid-rich conditions

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACL.2015.05.002

7 January 2021

Rate of production of plasma and very-low-density lipoprotein (VLDL) apolipoprotein C-III is strongly related to the concentration and level of production of VLDL triglyceride in male subjects with different body weights and levels of insulin sensit

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACL.2015.05.002

7 January 2021

Increased plasma apolipoprotein C-III concentration independently predicts cardiovascular mortality: the Hoorn Study

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACL.2015.05.002

7 January 2021

ApoCIII-enriched LDL in type 2 diabetes displays altered lipid composition, increased susceptibility for sphingomyelinase, and increased binding to biglycan

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACL.2015.05.002

7 January 2021

Common variants APOC3, APOA5, APOE and PON1 are associated with variation in plasma lipoprotein traits in Greenlanders

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACL.2015.05.002

7 January 2021

Dietary interventions that lower lipoproteins containing apolipoprotein C-III are more effective in whites than in blacks: results of the OmniHeart trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACL.2015.05.002

7 January 2021